Animal Model Summary Overview
The animal model summaries and descriptions have been curated by the National Institutes of Health (NIH) Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) Preclinical Working Group with support from the Foundation for the National Institutes of Health (FNIH). New and updated information, including detailed individual animal model pages, will be provided as more scientific studies are shared. Please continue to check back for more information.
Feedback, comments, and questions are highly encouraged to further develop these pages. Please contact ACTIVpreclinical@fnih.org.
Additional ACTIV Preclinical Resources
The ACTIV Preclinical Working Group has produced two valuable sources to help researchers develop their COVID-19 projects.
Accelerated Preclinical Paths to Support Rapid Development of COVID-19 Therapeutics
Grobler, JA, et al. Cell Host & Microbe (2020), doi: https://doi.org/10.1016/j.chom.2020.09.017
Abstract
ACTIVating Resources for the COVID-19 Pandemic: In vivo Models for Vaccines and Therapeutics
Hewitt, JA., et al. Cell Host & Microbe (2020), doi: https://doi.org/10.1016/j.chom.2020.09.016
Abstract

Small Animals

Species Modification Model Name/Nomenclature
Vaccines
Antivirals
Neutralizing Antibodies
Other Therapies
Infectivity
Transmission
Disease Enhancement
Disease Manifestation & Pathology Extent of disease
Updated:



Non-Human Primates

Species Geographic Origin Route of Exposure
Vaccines
Antivirals
Neutralizing Antibodies
Other Therapies
Infectivity
Transmission
Disease Enhancement
Disease Manifestation & Pathology Extent of disease
Updated:


= The model can be used to evaluate the noted agent type.
Y = Yes
N = No
TBD = *To be determined (TBD) entries indicate those for which there is either in progress relevant research studies or an absence of data in the current literature.
Other Therapies = Includes immunomodulators.